Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer

Neil D. Gross¹*, Julie E. Bauman²**, William E. Gooding³, William Denq⁴, Sufi M. Thomas⁴,⁵, Lin Wang⁶, Simion Chiosea⁴,⁶, Brian L. Hood⁷,⁸, Melanie S. Flint⁷, Mai Sun⁷, Thomas P. Conrads⁷,⁸, Robert L. Ferris⁴, Jonas T. Johnson⁴, Seungwon Kim⁴, Athanassios Argiris²,⁹, Lori Wirth¹⁰, Marina N. Nikiforova⁶, Jill M. Siegfried⁷,¹¹, Jennifer R. Grandis⁴

*These authors contributed equally to this work.

Author Affiliations:

¹ Department of Otolaryngology – Division of Head and Neck Surgery, Oregon Health and Science University

² Department of Internal Medicine – Division of Hematology/Oncology, University of Pittsburgh, University of Pittsburgh Cancer Institute

³ Biostatistics Facility, University of Pittsburgh, University of Pittsburgh Cancer Institute

⁴ Department of Otolaryngology, University of Pittsburgh

⁵ Present Affiliation: Department of Otolaryngology, University of Kansas Medical Center

⁶ Department of Pathology, University of Pittsburgh
Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute

Present Affiliation: Women’s Health Integrated Research Center, Gynecologic Cancer Center of Excellence, Annandale, VA

Present Affiliation: Department of Medicine – Division of Hematology/Oncology, University of Texas Health Science Center at San Antonio

Department of Medicine, Massachusetts General Hospital

Present Affiliation: Department of Pharmacology, University of Minnesota, Minneapolis, MN 55455

Running Title: Erlotinib, erlotinib-sulindac vs. placebo in operable HNSCC

Keywords: erlotinib, sulindac, phase 0, head and neck cancer, pSrc

Financial support: This work was supported by grants from the National Institutes of Health [R01CA098372; the UPCI Head and Neck Cancer SPORE (P50CA097190), the UPCI Cancer Center Support Grant (P30CA47904)]; the American Cancer Society Distinguished Professorship (to JRG); and OSI Pharmaceuticals.

*Corresponding Author:

Julie E. Bauman, MD, MPH

University of Pittsburgh Cancer Institute

5150 Centre Ave., 5th floor

Pittsburgh, PA 15232
Authors declare no conflict of interest for the submitted work.

Word count: 3361

Tables and Figures: 6

Supplemental Tables and Figures: 3
Translational Relevance

The epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) pathways are upregulated in head and neck squamous cell carcinoma (HNSCC). Crosstalk potentiates growth, proliferation and invasion. Preclinical models indicate synergistic anti-tumor activity from dual blockade. We conducted a phase 0 trial of erlotinib, an EGFR inhibitor; erlotinib plus sulindac, a non-selective COX inhibitor; vs. placebo in operable HNSCC in order to mechanistically characterize dual targeting. We demonstrated significant down-modulation of the tumor Ki-67 proliferation index in both groups treated with erlotinib, and a formal test of trend evidenced potentiation by sulindac. Further, we identified baseline pSrc expression as a candidate biomarker of erlotinib resistance in the clinic. This window trial provides the first in-human mechanistic data to justify efficacy trials of dual EGFR-COX inhibition in HNSCC. pSrc warrants investigation as a resistance biomarker for EGFR inhibition, and is now under investigation as a bona fide molecular target in HNSCC.
**Purpose:** The epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) pathways are upregulated in head and neck squamous cell carcinoma (HNSCC). Preclinical models indicate synergistic anti-tumor activity from dual blockade. We conducted a randomized, double-blind, placebo-controlled window trial of erlotinib, an EGFR inhibitor; erlotinib plus sulindac, a non-selective COX inhibitor, vs. placebo.

**Experimental Design:** Patients with untreated, operable Stage II-IVb HNSCC were randomized 5:5:3 to erlotinib, erlotinib-sulindac, or placebo. Tumor specimens were collected before and after 7-14 days of treatment. The primary endpoint was change in Ki-67 proliferation index. We hypothesized an ordering effect in Ki-67 reduction: erlotinib-sulindac > erlotinib > placebo. We evaluated tissue microarrays by immunohistochemistry for pharmacodynamic modulation of EGFR and COX-2 signaling intermediates.

**Results:** From 2005-2009, 47 patients were randomized for the target 39 evaluable patients. Thirty-four tumor pairs were of sufficient quality to assess biomarker modulation. Ki-67 was significantly decreased by erlotinib or erlotinib-sulindac (omnibus comparison, two-sided Kruskal-Wallis, p=0.04). Wilcoxon pairwise contrasts confirmed greater Ki-67 effect in both erlotinib groups (erlotinib-sulindac vs. placebo p=0.043; erlotinib vs. placebo, p=0.027). There was a significant trend in ordering of Ki-67 reduction: erlotinib-sulindac > erlotinib > placebo (two-sided exact Jonckheere-Terpstra, p =0.0185). Low baseline pSrc correlated with greater Ki-67 reduction (R² = .312, p = 0.024).
**Conclusions:** Brief treatment with erlotinib significantly decreased proliferation in HNSCC, with additive effect from sulindac. Efficacy studies of dual EGFR-COX inhibition are justified. pSrc is a potential resistance biomarker for anti-EGFR therapy, and warrants investigation as a molecular target.
Introduction

The epidermal growth factor receptor (EGFR), a transmembrane receptor tyrosine kinase (RTK) propagating proliferative and anti-apoptotic signals, is amplified and/or overexpressed in approximately 90% of head and neck squamous cell carcinoma (HNSCC). (1, 2) EGFR expression is higher in cancers driven by environmental carcinogens than by human papillomavirus (HPV) (3), and correlates with increased stage, reduced survival, and radioresistance. (1, 2, 4) EGFR signaling is also deregulated by HPV oncoproteins independent of EGFR expression level. (5) EGFR has been validated as a therapeutic target in phase III trials enrolling both HPV-positive and negative patients. (6, 7) Yet absolute benefit is low, and intrinsic resistance to the monoclonal antibody, cetuximab, or small molecule RTK inhibitors (gefitinib, erlotinib) is implied by low monotherapeutic response rates. (8, 9) Predictive biomarkers for sensitivity to EGFR inhibition represent a major unmet need in HNSCC. Activating mutations in the EGFR kinase domain, associated with clinical response in lung cancer, are rarely identified in HNSCC. (10) Furthermore, no alternative biomarker has been found. (11, 12)

In HNSCC, an important mechanism of EGFR activation is autocrine secretion of EGFR ligands. G protein-coupled receptors (GPCRs) transactivate EGFR by triggering proteolytic shedding of membrane-bound proligrands. (13, 14) GPCR-EGFR crosstalk may represent a targetable upstream resistance mechanism to EGFR blockade. (15-17) Cyclooxygenase-2 (COX-2), an inflammatory enzyme
which synthesizes the GPCR ligand PGE2, is upregulated in HNSCC and amenable to targeting by non-steroidal anti-inflammatory drugs (NSAIDs). Available NSAIDs, including the non-selective COX inhibitor sulindac, inhibit HNSCC cell growth in vitro, and suppress formation of preneoplastic lesions in a transgenic HNSCC model.(18) Concurrent EGFR-COX targeting demonstrates therapeutic synergism in HNSCC cell line and xenograft models.(17, 19, 20)

We conducted a randomized, double-blind, placebo-controlled window trial of erlotinib-sulindac, erlotinib or placebo-control in patients with HNSCC planned for definitive surgery. We analyzed paired, pre- and post-treatment tumor specimens for modulation of the Ki-67 proliferation index, to test the hypothesis that dual EGFR-COX targeting would potentiate anti-tumor effects relative to EGFR inhibition alone. We studied associated pharmacodynamic changes in EGFR-GPCR signaling intermediates, to identify predictive biomarkers for anti-EGFR therapy which may translate to the clinic.

Materials and Methods

Ethics Statement

This multicenter trial was approved by the Institutional Review Boards of the University of Pittsburgh (UP), Oregon Health Sciences University, and the Portland Veterans Administration Medical Center. The trial was nationally registered at clinicaltrials.gov (NCT01515137). All subjects provided written, informed consent.

Eligibility Criteria
Eligible subjects met the following key inclusion criteria: histologically confirmed, previously untreated HNSCC (Stage II-IVA) of the oral cavity, oropharynx, hypopharynx, or larynx, as defined by the American Joint Committee on Cancer Staging Handbook, 6th edition; planned complete resection of the primary tumor; age ≥ 18 years; Eastern Cooperative Oncology Group performance status 0-1; adequate hematologic, hepatic and renal function. Key exclusion criteria included: prior history of HNSCC; hypersensitivity to NSAIDs; interstitial lung disease; chronic use of NSAIDs or steroids.

Treatment

Subjects were randomized by the UP Biostatistics Facility to one of three neoadjuvant treatment groups: erlotinib (150 mg daily), erlotinib (150 mg daily) plus sulindac (150 mg twice daily), or placebo (for erlotinib) in a 5:5:3 ratio. There was no placebo for sulindac. Pre-operative therapy was administered in double-blind fashion for 7-14 days and discontinued 24-36 hours prior to surgery. Concomitant use of non-study NSAIDs or steroids was disallowed. Toxicities were described according to NCI Common Terminology Criteria for Adverse Events, version 3.0. Pre- and post-treatment tumor specimens were obtained at the time of diagnostic evaluation and definitive resection. Specimens were formalin-fixed and paraffin-embedded (FFPE), then shipped to UP for centralized analyses.

Statistical Methods
The reported window trial was originally nested in a single-arm, phase II study of adjuvant, open-label erlotinib following primary surgery and (chemo)radiation for locally advanced HNSCC. All subjects entering the parent trial were first randomized to one of three pre-operative treatment groups. After enrollment of 30 patients, the parent trial was discontinued due to non-feasibility. At the time of discontinuation, and prior to analysis of biospecimens, the nested window trial was redesigned as an independent study. Patient allocation and randomization were unaffected. The primary endpoint was defined as change in the Ki-67 proliferation index ($\Delta$Ki-67) in pre and post-treatment tumor specimens, as validated in neoadjuvant breast cancer trials. We hypothesized differential $\Delta$Ki-67 according to treatment group. With 39 patients randomized 5:5:3, we had 92% power at $\alpha=0.05$ for a two-sided Kruskal-Wallis test to detect an omnibus between-group difference of 1 log in $\Delta$Ki-67. Over-sampling was permitted to reach the target of 39 evaluable patients, defined as being randomized, undergoing neoadjuvant treatment, and providing at least one tissue specimen. We further hypothesized an ordering in Ki-67 down-modulation, with erlotinib-sulindac > erlotinib > placebo; an exact, two-sided Jonckheere-Terpstra test formally evaluated for this trend. Pairwise contrasts were evaluated by two-sided Wilcoxon tests. Exact two-sided Kruskal-Wallis tests evaluated for randomization imbalances. For the observed randomization imbalance in baseline Ki-67 (Kruskal-Wallis, $p = 0.022$), we used analysis of covariance to model the within-group association between baseline and change. Using adjusted values from this model we verified that the baseline imbalance did not
confound analysis of treatment group differences in ΔKi-67 (Supplemental Figure 1). Thus, the presented analysis is based upon observed data.

Secondary endpoints included modulation of 25 candidate protein biomarkers, including 21 empirically selected from pre-clinical signaling models and 4 from mass spectrometry (MS) discovery. Prior to analysis in February 2013, we proposed two biomarker tiers, with specialized alpha spending for priority, hypothesis-driven analytes. For tests of trend, we designated three priority analytes: ΔpSrc, ΔpAkt, and ΔpSTAT.(17, 24-28) We hypothesized that phosphorylated forms of these key EGFR signaling nodes mediated short-term changes in proliferative signaling. We used the Jonckheere-Terpstra statistic to test the hypothesis that a valid biomarker would recapitulate the ordering of Ki-67 down-modulation, that is, erlotinib-sulindac > erlotinib > placebo. For analyses of covariance, we defined four priority baseline proteins which could mechanistically explain resistance to Ki-67 modulation: pSrc, pAkt, pSTAT and COX-2. We first estimated flexible parametric regression models to evaluate the association of each baseline protein with ΔKi-67 across treatment groups. Significant baseline proteins were then tested for treatment group differences with analysis of covariance. For priority analytes, significance was set at α=0.05. The remaining analytes were exploratory; multiple testing was corrected for false discovery by the method of Benjamini and Hochberg.(29)

Specimen Analysis
The primary method for analyzing biomarker response was immunohistochemical (IHC) analysis of tissue microarrays (TMA). Using guiding H&E staining from FFPE blocks, 0.6 mm cores were transferred in triplicate from each pre- and post-treatment block to a blank recipient block. TMAs were assembled and stained after all tumor specimens had been submitted to minimize technical variation.

Pharmacodynamic modulation of Ki-67 and candidate biomarkers was evaluated by IHC of the TMA. Antibodies, clones, company, dilution and retrieval technique are summarized in Supplemental Table 1. Biomarkers, including Ki-67, were scored quantitatively with Aperio computer-assisted digital analysis by the research pathologist (LW), who was blinded to patient identity, treatment assignment, and specimen time-point. In keeping with international consensus guidelines for Ki-67, at least 5000 tumor cells/specimen were counted. The percentage of positive tumor cells was represented as the proliferation index.(30) Tumors were stained for p16, a recognized surrogate for HPV in the oropharynx, and classified as p16(+) if ≥ 70% of neoplastic cells demonstrated strong and diffuse nuclear and cytoplasmic staining.(31)

**Mass Spectrometry**

As an unbiased source of biomarker discovery, 10 post-treatment specimens (5 erlotinib-treated, 5 placebo-treated) were evaluated by MS for differential protein expression. Tissues were prepared and digested with trypsin as described.(32) A false peptide discovery rate of less than 2% was determined by searching the
primary tandem MS data using the same criteria against a decoy database. Differences in protein abundance were derived by spectral counting. 7390 proteins were filtered for low variability; the remaining 610 proteins were analyzed by Wilcoxon test for differential expression. Among 73 proteins with an unadjusted p-value < 0.10, four had a commercially available antibody for IHC, and were analyzed in trial specimens: gelsolin, calreticulin, desmoglein and GAPDH.

**PIK3CA Mutation Testing**

DNA was isolated from tumor cores and tested for mutations in exons 9 and 20 of the PIK3CA gene as described.

**Results**

**Enrollment and Baseline Characteristics**

Between December 2005 and December 2008, 47 subjects enrolled across three study centers in order to meet the evaluable target of 39. Patient allocation is presented in the Consort Diagram (Figure 1). Baseline characteristics for the 46 subjects who received at least one dose of neoadjuvant study drug are summarized in Table 1. Subjects were well-balanced among groups with respect to age, gender, disease site, stage, and p16 status. This was a largely HPV-negative cohort; only 2 of 14 oropharynx tumors were p16(+).

**Toxicity**
Brief exposure to erlotinib, erlotinib-sulindac, or placebo was well tolerated in the pre-operative setting. Clinically significant toxicities attributed to study treatment are summarized in Table 2. Adverse events represented typical class toxicities for EGFR inhibitors, including rash and diarrhea.(36) One patient discontinued study treatment for grade 2 anxiety, and one required erlotinib dose-reduction for grade 2 mucositis. Median hospitalization for surgery was 9 days. No unusual rate or type of post-operative complication was observed; complications included fistula (2), wound infection (2), free flap necrosis (1), prolonged intubation (2), infection outside the surgical field (2) and bleeding (1).

Biomarker Modulation

Evaluable tissue for analysis of at least one paired-specimen biomarker was available from 34 of 39 patients (87%); and for at least one baseline protein was available from 35 of 39 patients (90%). Depending upon the biomarker assayed, 49 - 92% of the 34 paired specimens (median 78%) had measurable protein in both samples.

Ki-67. Twenty-seven patients (69%) had measurable Ki-67 in both samples. The primary, omnibus hypothesis test demonstrated a significant between-group difference in ΔKi-67 (Kruskal-Wallis, two-sided, p=0.04). Box-plots depicting treatment group medians and inter-quartile ranges are presented in Figure 2A. There was no change in Ki-67 attributable to placebo. As compared to placebo, Ki-67 was significantly modulated by erlotinib (p=0.04) or erlotinib-sulindac (p=0.03). There was a significant trend in ordering of Ki-67 down-modulation:
erlotinib-sulindac > erlotinib > placebo (Exact Jonckheere-Terpstra, two-sided, p=0.02), indicating additive anti-proliferative effect from sulindac. A waterfall plot depicting per-patient percent change in Ki-67 is shown in Figure 2B.

**Biomarker Intermediates.** We hypothesized that pSrc, pAkt, or pSTAT mediated the significant reduction in Ki-67 by erlotinib or erlotinib-sulindac. If valid signaling intermediates of reduced proliferation, changes in these proteins would directly correlate with the ordering of $\Delta$Ki-67. As shown in Figures 3A and 3B, none of the three priority analytes, nor 22 exploratory biomarkers, demonstrated a significant ordering effect.

**Resistance Biomarkers.** We hypothesized that increased baseline pSrc, pAkt, pSTAT or COX-2 might mediate resistance to Ki-67 modulation. We first evaluated the association between baseline expression of these candidate resistance biomarkers and $\Delta$Ki-67, independent of randomized treatment assignment (Figure 4A). Higher pre-treatment pSrc was associated with a smaller decrease in Ki-67 ($R^2 =0.3$, $p = 0.04$). To understand whether these findings might represent erlotinib resistance, we plotted pSrc against $\Delta$Ki-67 within each treatment group. As displayed in Figure 4B, resistance to Ki-67 modulation was demonstrated only in the active treatment groups (tests that slopes differ from 0: placebo, $p=0.8775$; erlotinib, $p=0.0024$; erlotinib-sulindac, $p=0.0150$). Collectively, these findings implicate high baseline pSrc expression as a resistance biomarker to erlotinib, irrespective of co-treatment with sulindac. No significant association between baseline expression of 21 exploratory biomarkers and Ki-67 modulation was discovered (Supplemental Figure 2).
PIK3CA Mutations

Because PIK3CA mutations are associated with chemopreventive benefit from aspirin in patients with colorectal cancer(37), we conducted a post hoc correlation between PIK3CA mutation status and ΔKi-67 in the erlotinib-sulindac arm. Two of 9 patients harbored non-common exon 9 mutations (p.E522K, c.1564G>A; p.A533V, c.1598C>T AND p.I543I, c.1629C>T) while one bore a canonical exon 20 mutation (H1047L, c.3140 A>T). There was no relationship between mutation status and ΔKi-67 (data not shown).

Discussion

While EGFR has been validated as the first molecular target in HNSCC, absolute improvement in a clinically reliable endpoint following exposure to an EGFR inhibitor is limited to 10-20% of patients, implicating intrinsic resistance despite EGFR over-expression in the vast majority.(6, 7, 9) Predictive biomarkers for anti-EGFR therapy in HNSCC represent a major unmet need. The current trial took advantage of a window design to investigate mechanistic signaling hypotheses regarding response and resistance to short-term erlotinib, with or without sulindac, in HNSCC. The study met its primary endpoint. First, we observed differential down-modulation of the Ki-67 proliferation index across treatment groups, attributable to erlotinib or erlotinib-sulindac as compared to placebo. Second, we confirmed that sulindac potentiates the anti-proliferative effect of erlotinib in a formal test of trend, indicating that the forward feedback
loop between COX-2 and EGFR is a relevant clinical target. Finally, we identified baseline pSrc expression as a potential resistance biomarker to erlotinib. Study results were strengthened by incorporation of a placebo-control. Lack of significant change in Ki-67 in placebo-treated patients raised confidence in its validity as a primary biomarker endpoint. Conversely, recognition of background changes in GPCR-EGFR signaling intermediates in placebo-treated patients avoided over-stated mechanistic conclusions.

Ki-67 is a nuclear non-histone protein expressed in proliferating human tissue.(38) While recognized as a poor prognostic marker in breast cancer, the Ki-67 proliferation index is inconsistently prognostic in HNSCC.(39, 40) ΔKi-67 is a validated surrogate biomarker in neoadjuvant studies of targeted therapy in breast cancer(22, 23), however relevance to HNSCC window trials is unknown as Ki-67 modulation has not been evaluated directly against clinical outcome.(41-43) Here, the non-feasibility of adjuvant erlotinib in the parent trial precluded our planned correlation of ΔKi-67 and 3-year PFS. An alternate surrogate biomarker, the TUNEL apoptotic index, was evaluated in a randomized window trial of lapatinib vs. placebo in HNSCC.(41) Although apoptosis was increased by lapatinib, the increase was not significant against placebo, underscoring the value of placebo-control in short-term biomarker modulation studies. Notably, the Ki-67 proliferation index was significantly decreased by lapatinib vs. placebo, in line with our results. Collectively, these data suggest that proliferation is a more robust short-term endpoint than apoptosis for assessing response to targeted therapy in HNSCC.
The major secondary objective of this window study was identification of GPCR-EGFR signaling intermediates responsible for pharmacodynamic change in Ki-67. However, among 25 protein candidates, none demonstrated an ordering effect consistent with ΔKi-67. Preclinical HNSCC models demonstrate at-least additive downregulation of multiple phospho-proteins (eg. pSrc, pAkt, and pSTAT3) by GPCR-EGFR co-inhibition relative to EGFR inhibition alone.(17, 20) Our hypothesis test requiring linear ordering of valid intermediates may not reflect in vivo complexity of the GPCR-EGFR signaling network. The candidate biomarker approach was further limited by availability of validated commercial antibodies. Of note, multiple signaling proteins changed significantly in placebo-treated patients, raising questions regarding tissue heterogeneity, stability of signaling patterns during placebo treatment, and assay reliability. While we attempted to mitigate these variables by standardized tissue collection/processing, single-batch antibody staining and blinded, centralized review, methodologic limitations for quantifying protein expression changes must be emphasized. This parallels our recent report demonstrating no significant differences between treatment and placebo groups in serum protein expression from this trial.(44) As multiplex proteomics technologies are piloted for pharmacodynamic assessment, placebo-controlled data will be critical to avoiding Type I error.

The paucity of predictive biomarkers for EGFR targeting in HNSCC impairs selection of patients who will benefit, and redirection of those who will not. This study identified high baseline pSrc expression as a potential resistance
biomarker for erlotinib, an observation consistent with mechanistic preclinical data. Src family kinases are activated in response to EGFR signaling.(13, 45) GPCRs also activate pSrc upstream of EGFR, recruiting pSrc to the complex mediating EGFR transactivation.(17) Finally, pSrc drives ligand-independent activation of cMet, a major resistance mechanism to erlotinib in HNSCC models.(46, 47) Because sulindac reduces PGE2-GPCR activation, and as a consequence pSrc(17), we hypothesized that the association between pSrc and resistance to Ki-67 modulation would be muted in the sulindac group. This was not the case, suggesting that baseline pSrc is not driven dominantly by PGE2, but the convergent influence of multiple GPCR ligands and accessory RTKs. Contrary to our hypothesis, no other GPCR-EGFR signaling protein was associated with ΔKi-67, including the PI3K/Akt and STAT3 resistance nodes described in preclinical models.(17, 20) Although we recently reported that PIK3CA mutations are associated with erlotinib resistance in HNSCC cell lines(48), this has not been observed in HNSCC clinical cohorts. Here, PIK3CA mutation status in the erlotinib-sulindac arm did not correlate with ΔKi-67; this post-hoc finding warrants cautious interpretation due to small sample size and the potential interaction between genomic activation of PIK3CA and NSAIDs.(37)

This study has several important limitations. First, the CONSORT diagram (Figure 1) highlights the challenges in executing window studies. Although 35 of 39 patients had sufficient quality tissue for analysis of one biomarker, only 27 (69%) pairs were analyzable for the primary endpoint. Second, a sulindac-alone arm was not incorporated. This decision was based upon two factors: 1) EGFR is
an established therapeutic target in HNSCC whereas NSAIDs alone have not proven effective; 2) our biomarker hypothesis emphasized the potentiation of EGFR inhibition by sulindac, in the setting of GPCR-EGFR transactivation. Third, a potential criticism is use of Ki-67 IHC as the primary endpoint, given the observed heterogeneity of tumor protein expression and unknown reliability of many IHC antibodies. Although Ki-67 is subject to variability from pre-analytic processing and inter-observer scoring, the MIB1 antibody has been well-validated, is tolerant of a range of fixation times, demonstrates durable antigenicity, and is the subject of international consensus standards followed here.(30) Finally, the absence of a clinical endpoint limits interpretation of our mechanistic findings. Correlation of ΔKi-67 to radiologic response or disease outcome will be critical to validating Ki-67 modulation as a short-term biomarker endpoint in HNSCC window trials.

Despite acknowledged limitations, we affirmed that erlotinib significantly reduced proliferation in operable HNSCC after short-term exposure, an effect potentiated by sulindac. Efficacy studies evaluating dual EGFR-COX-2 targeting are justified, particularly in light of a phase I clinical trial of gefitinib and celecoxib, demonstrating a 22% response rate in recurrent/metastatic HNSCC.(49) Such a strategy may be more fruitful in patients with low tumoral pSrc expression, based upon our identification of baseline pSrc as a candidate resistance biomarker for erlotinib. Given pSrc’s central role in activating compensatory pathways, pSrc also warrants investigation as a "bona fide" co-target in HNSCC. Although the Src family kinase inhibitor, dasatinib, demonstrated limited single agent activity in
HNSCC(50), dual EGFR-Src inhibition remains of interest. Two translational studies are ongoing in HNSCC, including the combination of erlotinib-dasatinib in the window setting, and cetuximab-dasatinib in the recurrent/metastatic setting (NCT00779389; NCT01488318).

**Grant support:** This work was supported by grants from the National Institutes of Health [R01CA098372; the UPCI Head and Neck Cancer SPORE (P50CA097190), the UPCI Cancer Center Support Grant (P30CA47904)]; the American Cancer Society Distinguished Professorship (to JRG); and OSI Pharmaceuticals.


Table 1. Subject Characteristics by Treatment Group

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N = 12)</th>
<th>Erlotinib (N = 18)</th>
<th>Erlotinib + Sulindac (N = 16)</th>
<th>Test of Equality¹</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median range</td>
<td>59</td>
<td>64</td>
<td>49</td>
<td>.8976</td>
</tr>
<tr>
<td>range</td>
<td>33 - 86</td>
<td>44 - 73</td>
<td>49 - 68</td>
<td></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>3 25</td>
<td>4 22</td>
<td>3 19</td>
<td>.9924</td>
</tr>
<tr>
<td>Male</td>
<td>9 75</td>
<td>14 78</td>
<td>13 81</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor Site</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral Cavity</td>
<td>8 67</td>
<td>9 50</td>
<td>9 56</td>
<td>.6606</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>3 35</td>
<td>5 28</td>
<td>6 38</td>
<td></td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0 0</td>
<td>2 11</td>
<td>0 0</td>
<td></td>
</tr>
<tr>
<td>Larynx</td>
<td>1 8</td>
<td>2 11</td>
<td>1 6</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor (T) Stage²</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 9</td>
<td>0 0</td>
<td>0 0</td>
<td>.2371</td>
</tr>
<tr>
<td>2</td>
<td>5 45</td>
<td>3 18</td>
<td>3 20</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3 28</td>
<td>4 24</td>
<td>5 33</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>2 18</td>
<td>10 59</td>
<td>7 47</td>
<td></td>
</tr>
<tr>
<td><strong>Nodal (N) Stage³</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>7 70</td>
<td>8 44</td>
<td>6 40</td>
<td>.3389</td>
</tr>
<tr>
<td>1</td>
<td>1 10</td>
<td>4 22</td>
<td>6 40</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2 20</td>
<td>6 33</td>
<td>2 13</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0 0</td>
<td>0 0</td>
<td>1 7</td>
<td></td>
</tr>
<tr>
<td><strong>p16 Status⁴</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>1 11</td>
<td>3 20</td>
<td>0 0</td>
<td>.3579</td>
</tr>
<tr>
<td>Negative</td>
<td>10 89</td>
<td>12 80</td>
<td>11 100</td>
<td></td>
</tr>
</tbody>
</table>

1. Wilcoxon Test for age, Fisher’s exact two-tailed test for others
2. T classification was not available for 3 subjects.
3. N classification was not available for 3 subjects.
4. p16 status was not available for 9 patients. Among 14 oropharynx cases, 11 were p16(-), 2 were p16(+), and 1 was unknown.
Table 2. Toxicities

<table>
<thead>
<tr>
<th>Nonhematologic Toxicity</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Total Grade ≥ 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy/Immunology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity</td>
<td>1 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Constitutional</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>3 (7%)</td>
<td>2 (4%)</td>
<td>1 (2%)</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Dermatologic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rash/desquamation</td>
<td>11 (24%)</td>
<td>5 (11%)</td>
<td>2 (4%)</td>
<td>0</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>0</td>
<td>1 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>4 (9%)</td>
<td>1 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mucositis/Stomatitis</td>
<td>1 (2%)</td>
<td>1 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (4%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neurologic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety</td>
<td>0</td>
<td>1 (2%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
Table 1. Subject Characteristics by Treatment Group

Table 2. Toxicities

Figure 1. CONSORT diagram. This flow chart depicts the number of patients who signed consent, were randomized and treated, and ultimately provided paired tumor specimens of sufficient quality for biomarker analysis.

Figure 2. The Primary Endpoint, Ki-67 Proliferation Index. (A) The primary omnibus hypothesis demonstrated a significant difference in Ki-67 modulation among groups (two-sided Kruskal-Wallis, p=0.04). Depicted in this box and whisker plot are the Wilcoxon pairwise contrasts confirming a significant decrease in Ki-67 for patients treated with either erlotinib or erlotinib-sulindac vs. placebo. Box and whisker plots consist of the median (white line), the inter-quartile range (box) and the distance to observed values within 1.5 times the inter-quartile range (whiskers). (B) A waterfall plot depicts the intra-patient change in tumoral Ki-67 expression, pre and post-treatment. Bars are color-coded according to treatment arm.

Figure 3. Biomarker Intermediates and ΔKi-67. We hypothesized that constituents of the EGFR or COX-2 signaling pathways may mediate the observed change in proliferation. The line represents restricted cubic-spline fit for the relationship between Δanalyte and ΔKi-67. No significant correlation was identified between ΔKi-67 and the priority analytes, ΔpSTAT3, ΔpSrc, or ΔpAkt (A) or 21 other candidate biomarkers (B).

Figure 4. Baseline pSrc and ΔKi-67. (A) Four priority baseline analytes (pSrc, pAkt, pSTAT3 and COX-2) were evaluated for association with Ki-67 modulation, with the line representing restricted cubic-spline fit. Higher pre-treatment pSrc was associated with a smaller decrease in Ki-67 following neoadjuvant treatment. (B) Baseline pSrc was plotted against ΔKi-67 for each color-coded treatment group. A significant association was noted only in the active treatment groups (tests that slopes differ from 0: placebo, p=0.8775; erlotinib, p=0.0024; erlotinib-sulindac, p=0.0150), forwarding baseline pSrc as a candidate biomarker of erlotinib resistance.
Figure 1

Enrollment

Signed informed consent (n=49)

Excluded (n=2)

- Not meeting inclusion criteria (2)

Allocation

Randomized (n=47)

Placebo (n=13)

- Received intervention (12)

- ≥1 paired specimen (10)

Erlotinib (n=15)

- Received intervention (15)

- Subject refused (1)

Analysis

Placebo (n=12)

- Paired Ki-67 (8)

Erlotinib (n=10)

- Paired Ki-67 (3)

- ≥1 paired specimen (13)

Erlotinib + Sulindac (n=16)

- Paired Ki-67 (8)

- ≥1 paired specimen (11)
Clinical Cancer Research

Erlotinib, erlotinib-sulindac vs. placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer


*Clin Cancer Res* Published OnlineFirst April 11, 2014.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-13-3360</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2014/04/16/1078-0432.CCR-13-3360.DC1">http://clincancerres.aacrjournals.org/content/suppl/2014/04/16/1078-0432.CCR-13-3360.DC1</a></td>
</tr>
<tr>
<td>Author Manuscript</td>
<td>Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.</td>
</tr>
</tbody>
</table>

**E-mail alerts** | Sign up to receive free email-alerts related to this article or journal. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Reprints and Subscriptions</strong></td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td><strong>Permissions</strong></td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>